THU0395 Tumour necrosis factor-alpha as a master regulator of inflammation in erdheim-chester disease: Rationale for the successful treatment of two patients with infliximab

Abstract

BackgroundErdheim-Chester disease (ECD) is a rare form of systemic non-Langerhans histiocytoses of unknown aetiology. IFN-α is the first-line therapy, but its efficacy varies according to sites of disease involvement. When...